Skip to content
Dedifferentiated Liposarcoma (DDL) Resources for Healthcare Professionals | Wiley Knowledge Hub
  • About
  • Stay Up To Date

Follow by Email
Facebook
fb-share-icon
LinkedIn
Share

DEDIFFERENTIATED LIPOSARCOMA

  • Home
  • Articles
  • Webinar
  • Infographics
  • KOL Commentaries
  • Faculty
Dedifferentiated Liposarcoma (DDL) Resources for Healthcare Professionals | Wiley Knowledge Hub

DEDIFFERENTIATED LIPOSARCOMA

Search for:
  • Home
  • Articles
  • Webinar
  • Infographics
  • KOL Commentaries
  • Faculty
  • About
  • Stay Up To Date

PSMA and FDG PET/CT Findings in Patient With Dedifferentiated Liposarcoma and Prostate Cancer Metastases

Article / By Wiley Knowledge Hub

PSMA and FDG PET/CT Findings in Patient With Dedifferentiated Liposarcoma and Prostate Cancer Metastases Read More »

New targeted therapies in liposarcoma: state of art and future perspectives

Article / By Wiley Knowledge Hub

New targeted therapies in liposarcoma: state of art and future perspectives Read More »

Diagnosing liposarcoma on (peri)-renal mass biopsy: A clinicopathological study of 30 cases

Article / By Wiley Knowledge Hub

Diagnosing liposarcoma on (peri)-renal mass biopsy: A clinicopathological study of 30 cases Read More »

GLI1 Co-Amplification in Well-differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases

Article / By Wiley Knowledge Hub

GLI1 Co-Amplification in Well-differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases Read More »

A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas

Article / By Wiley Knowledge Hub

A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas Read More »

First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial

Article / By Wiley Knowledge Hub

First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial Read More »

Complete resection after abemaciclib targeted therapy in a patient with mediastinal liposarcoma extensively invading the pericardium and major vessels

Article / By Wiley Knowledge Hub

Complete resection after abemaciclib targeted therapy in a patient with mediastinal liposarcoma extensively invading the pericardium and major vessels Read More »

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Article / By Wiley Knowledge Hub

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates Read More »

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Article / By Wiley Knowledge Hub

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial Read More »

Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Article / By Wiley Knowledge Hub

Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Read More »

Post pagination
← Previous 1 2 3 4 … 10 Next →

This Knowledge Hub is supported by Boehringer Ingelheim.

John Wiley & Sons in partnership with

Knowledge Hub

  • Home
  • Articles
  • Webinar
  • Infographics
  • KOL Commentaries
  • Faculty

About

  • About
  • Stay Up To Date
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 John Wiley & Sons, Inc. All rights reserved.

Cookie Preferences

Lost your password?

Start typing and press enter to start search